Clinical Trial: Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.

Brief Summary: To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.

Detailed Summary: To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival, as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population.
Sponsor: Teva Pharmaceutical Industries

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Teva Pharmaceutical Industries

Dates:
Date Received: June 6, 2003
Date Started: July 2003
Date Completion:
Last Updated: May 20, 2011
Last Verified: May 2011